Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of TMC558445 alone and with TMC310911 or darunavir in healthy adults
NL-OMON33802Phase 1Active, not recruiting
- Sponsor
- Tibotec
- Start
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TMC558445, TMC-310911 and darunavir in human immunodeficiency virus infection (HIV) (9 arms), sponsored by Tibotec. Started Feb 2009; status: active, not recruiting.
02
Drugs
TMC558445TMC-310911darunavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NL-OMON33802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33802.